Findings from new research indicate that the health of the gastrointestinal tract plays a significant role in bipolar disorder. This opens the door to new therapies. Dietary modification or anti-inflammatory treatment may prove to be more beneficial than the standard drugs often prescribed.
In the study, researchers examined levels of ASCA (anti-Saccharomyces cerevisiaeantibodies) which is a marker for gut inflammation. They found that elevated levels of ASCA were associated with a 3.5–4.4-fold increased risk for bipolar disorder, regardless of what medications the subjects were taking.